Global private equity and venture capital news and research

Posts Tagged ‘Forbion Capital Partners’

22 September 2016

Forbion reaps ‘considerable return’ from Akarna exit to Allergan

apothecary-pharmacy-chemist-mortar-and-pestle-39522 Forbion Capital Partners has gotten its money's worth from the sale of Akarna Therapeutics just seven months after investing in the company, AltAssets understands.

12 April 2016

Forbion closes third life science fund at €183m

medicine-791817_960_720 European venture capital firm Forbion Capital Partners has closed is third flagship life sciences fund at €183m ($208m).

28 September 2015

Atlas Venture-led consortium helps fund latest Replimune cancer research

lab-217041_1280 Early-stage investment firm Atlas Venture has headed a group of investors to successfully close a $30m financing round for Oxford-based cancer therapeutics firm Replimune.

17 September 2015

Forbion agrees exit of cholesterol drug developer Dezima for up to $1.55bn

fried-eggs-456351_1280 Dutch healthcare investment firm Forbion Capital Partners has agreed to $1.55bn sale of biotech business Dezima Pharma to trade player Amgen Inc.

11 September 2015

Coller, Hamilton Lane, others back Forbion co-investment fund

money-515058_1280 Life sciences-focused venture capital firm Forbion Capital Partners has held a €75m final close for a new co-investment fund aimed at backing later-stage deals in the portfolio of its second flagship fund.

8 September 2015

Ysios Capital leads €36.6m Series C for drug developer Sanifit

pills-530372_1280 Spanish early-stage investment firm Ysios Capital has led a €36.6m Series C investment round for clinical-stage biopharma business Laboratoris Sanifit.

26 May 2015

Quebec development capital fund FTQ makes €10.5m Forbion III commitment

life science green Quebec-focused development capital fund Fonds de solidarité FTQ has committed €10.5m to Forbion Capital Partners' third fund in an attempt to attract life sciences investment to the province.

24 March 2015

New VCs help anti-cancer treatment pioneer Rigontec push Series A to €14.25m

Dutch early stage investor Forbion Capital Partners and Danish peer Sunstone Capital have brought biopharma business Rigontec's Series A round to €14.25m through a second close.

5 August 2014

Forbion exits 2006 investment in Santaris to Roche for up to €450m

santaris Dutch early stage investment firm Forbion Capital Partners has sold Danish biopharmaceutical company Santaris Pharma to Roche in a deal worth up to $450m.

7 February 2014

Gene therapy company uniQure raises over $80m via IPO

biotech_lrg Venture capital-backed gene therapy specialist uniQure has raised nearly $82m via an IPO on the Nasdaq exchange, which was priced above the indicative range.

Page 1 of 212

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016